Prognostic Factors for Patients with Proliferative Hepatocellular Carcinoma After Liver Resection

References

• Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–630. doi:10.1016/j.jhep.2019.06.001
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572–582. doi:10.1148/radiol.2021204352
   PubMed Web of Science ®Google Scholar
• Bao Y, Li JX, Zhou P, et al. Identifying proliferative hepatocellular carcinoma at pretreatment ct: implications for therapeutic outcomes after transarterial chemoembolization. Radiology. 2023;308(2):e230457. doi:10.1148/radiol.230457
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma (vol 69, pg 182, 2018). Correct J Hepatol. 2019;70:182–236. doi:10.1016/j.jhep.2019.01.020
   Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Hwang S, Joh JW, Wang HJ, et al. Prognostic prediction models for resection of large hepatocellular carcinoma: a Korean multicenter study. World J Surg. 2018;42(8):2579–2591. doi:10.1007/s00268-018-4468-2
   PubMed Web of Science ®Google Scholar
• Ang SF, Ng ES, Li H, et al. The Singapore liver cancer recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10(4):e0118658. doi:10.1371/journal.pone.0118658
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (li-rads) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the liver Italian program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res. 2007;37(Suppl 2):S206–9. doi:10.1111/j.1872-034X.2007.00186.x
   PubMed Web of Science ®Google Scholar
• Chan EE, Chow PK. A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores. Jpn J Clin Oncol. 2017;47(4):287–293. doi:10.1093/jjco/hyw185
   PubMed Web of Science ®Google Scholar
• Kitao A, Matsui O, Zhang Y, et al. Dynamic CT and gadoxetic acid-enhanced MRI characteristics of p53-mutated hepatocellular carcinoma. Radiology. 2023;306(2):e220531. doi:10.1148/radiol.220531
   PubMed Web of Science ®Google Scholar
• Papageorge MV, de Geus SWL, Woods AP, et al. Surveillance patterns for hepatocellular carcinoma among screening-eligible patients in the medicare population. Ann Surg Oncol. 2022;29(13):8424–8431. doi:10.1245/s10434-022-12360-z
   PubMed Web of Science ®Google Scholar
• Borde T, Nezami N, Gaupp FL, et al. Optimization of the BCLC staging system for locoregional therapy for hepatocellular carcinoma by using quantitative tumor burden imaging biomarkers at MRI. Radiology. 2022;304(1):228–237. doi:10.1148/radiol.212426
   PubMed Web of Science ®Google Scholar
• Choi JH, Ro JY. Combined hepatocellular-cholangiocarcinoma: an update on pathology and diagnostic approach. Biomedicines. 2022;10(8):1826. doi:10.3390/biomedicines10081826
   PubMed Web of Science ®Google Scholar
• Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol. 2022;32(8):5119–5133. doi:10.1007/s00330-022-08643-4
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.Ccr-14-0442
   PubMed Web of Science ®Google Scholar
• Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and management. Am Fam Physician. 2019;100(12):759–770.
   PubMed Web of Science ®Google Scholar
• van der PCB, McInnes MDF, Salameh JP, et al. CT/MRI and CEUS LI-rads major features association with hepatocellular carcinoma: individual patient data meta-analysis. Radiology. 2022;302(2):326–335. doi:10.1148/radiol.2021211244
   PubMed Web of Science ®Google Scholar
• Zafar F, Lubert AM, Trout AT, et al. Abdominal CT and MRI findings of portal hypertension in children and adults with Fontan circulation. Radiology. 2022;303(3):557–565. doi:10.1148/radiol.211037
   PubMed Web of Science ®Google Scholar
• Elder RW, McCabe NM, Hebson C, et al. Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol. 2013;168(4):3764–3769. doi:10.1016/j.ijcard.2013.06.008
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975
   PubMed Web of Science ®Google Scholar
• Tümen D, Heumann P, Gülow K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022;10(12):3202. doi:10.3390/biomedicines10123202
   PubMed Web of Science ®Google Scholar
• Dhondt E, Lambert B, Hermie L, et al. 90YRadioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the trace phase ii randomized controlled trial. Radiology. 2022;303(3):699–710. doi:10.1148/radiol.211806
   PubMed Web of Science ®Google Scholar
• Liu G, Ma D, Wang H, et al. Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma. Insights Imaging. 2023;14(1):89. doi:10.1186/s13244-023-01427-4
   PubMed Web of Science ®Google Scholar
• Aoki T, Nishida N, Kudo M. Current perspectives on the immunosuppressive niche and role of fibrosis in hepatocellular carcinoma and the development of antitumor immunity. J Histochem Cytochem. 2022;70(1):53–81. doi:10.1369/00221554211056853
   PubMed Web of Science ®Google Scholar
• Liaskou E, Klemsdal Henriksen EK, Holm K, et al. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology. 2016;63(5):1608–1619. doi:10.1002/hep.28116
   PubMed Web of Science ®Google Scholar
• Moeini A, Torrecilla S, Tovar V, et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology. 2019;157(5):1383–1397.e11. doi:10.1053/j.gastro.2019.07.028
   PubMed Web of Science ®Google Scholar
• Li HZ, Liu QQ, Chang DH, et al. Identification of NOX4 as a new biomarker in hepatocellular carcinoma and its effect on sorafenib therapy. Biomedicines. 2023;11(8):2196. doi:10.3390/biomedicines11082196
   PubMed Web of Science ®Google Scholar
• Kwag M, Choi SH, Choi SJ, Byun JH, Won HJ, Shin YM. Simplified LI-RADS for hepatocellular carcinoma diagnosis at gadoxetic acid-enhanced MRI. Radiology. 2022;305(3):614–622. doi:10.1148/radiol.220659
   PubMed Web of Science ®Google Scholar
• Yeh CN, Chen MF, Lee WC, Jeng LB. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol. 2002;81(4):195–202. doi:10.1002/jso.10178
   PubMed Web of Science ®Google Scholar
• Wee IJY, Moe FNN, Sultana R, et al. Extending surgical resection for hepatocellular carcinoma beyond Barcelona clinic for liver cancer (BCLC) stage a: a novel application of the modified BCLC staging system. J Hepatocell Carcinoma. 2022;9:839–851. doi:10.2147/jhc.S370212
   PubMed Web of Science ®Google Scholar
• Bae JS, Lee JM, Jeon SK, et al. LI-RADS Tumor in Vein at CT and Hepatobiliary MRI. Radiology. 2022;302(1):107–115. doi:10.1148/radiol.2021210215
   PubMed Web of Science ®Google Scholar
• Tay BWR, Huang DQ, Mark M, et al. Comparable outcomes in early hepatocellular carcinomas treated with trans-arterial chemoembolization and radiofrequency ablation. Biomedicines. 2022;10(10):2361. doi:10.3390/biomedicines10102361
   PubMed Web of Science ®Google Scholar
• Tong Y, Li JX, Chang DH, et al. An integrated liver function, systemic inflammation, and tumor characteristic score predicts prognosis in hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2023;30(4):2007–2020. doi:10.1245/s10434-022-12899-x
   PubMed Web of Science ®Google Scholar